Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.
Nyquist MD, Ang LS, Corella A, Coleman IM, Meers MP, Christiani AJ, Pierce C, Janssens DH, Meade HE, Bose A, Brady L, Howard T, De Sarkar N, Frank SB, Dumpit RF, Dalton JT, Corey E, Plymate SR, Haffner MC, Mostaghel EA, Nelson PS.
Nyquist MD, et al. Among authors: janssens dh.
J Clin Invest. 2021 May 17;131(10):e146777. doi: 10.1172/JCI146777.
J Clin Invest. 2021.
PMID: 33998604
Free PMC article.